Zevra Therapeutics (ZVRA) EBT Margin (2019 - 2026)
Zevra Therapeutics (ZVRA) reported EBT Margin of 123.77% for Q1 2026, up 13316.0% on a YoY basis from N/an in Q1 2025, and up 233.9% quarter-over-quarter from 37.07% in Q4 2025.
Zevra Therapeutics (ZVRA) EBT Margin (2019 - 2026) Analysis & Trends
Zevra Therapeutics has reported EBT Margin for 8 years, with the latest figure at 123.77% in Q1 2026.
- For the quarter ending Q1 2026, EBT Margin rose 13316.0% year-over-year to 123.77%; the trailing twelve-month figure through Mar 2026 stood at 109.06% (up 29511.0% YoY), and the FY2025 full-year result was 81.41%, up 46317.0% from the prior year.
- EBT Margin for Q1 2026 stood at 123.77%, up from 37.07% in the prior quarter.
- The five-year high for EBT Margin was 297.15% in Q2 2025, with the low at 45691.67% in Q2 2022.
- Historically, EBT Margin has averaged 2929.57% across 5 years, with a median of 169.56% in 2024.
- Annual changes were most pronounced in 2022 — EBT Margin slumped 4574342 bps — and 2023, when it surged 4566042 bps.
- Zevra Therapeutics' EBT Margin stood at 1654.35% in 2022, then surged by 91 bps to 153.96% in 2023, then retreated by 10 bps to 169.56% in 2024, then soared by 122 bps to 37.07% in 2025, then soared by 234 bps to 123.77% in 2026.
- The last three EBT Margin figures came in at 123.77% (Q1 2026), 37.07% (Q4 2025), and 3.75% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 6.40% |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 41.95% |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Zevra Therapeutics | 704.96 Mn | 504.34 Mn | 34.30 Mn | 123.77% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 123.77% |
| Dec 31, 2025 | 37.07% |
| Sep 30, 2025 | -3.75% |
| Jun 30, 2025 | 297.15% |
| Mar 31, 2025 | -9.40% |
| Dec 31, 2024 | -169.56% |
| Sep 30, 2024 | -899.19% |
| Jun 30, 2024 | -451.25% |
| Mar 31, 2024 | -490.94% |
| Dec 31, 2023 | -153.96% |
| Sep 30, 2023 | -351.99% |
| Jun 30, 2023 | -31.25% |
| Mar 31, 2023 | -419.40% |
| Dec 31, 2022 | -1,654.35% |
| Sep 30, 2022 | -198.33% |
| Jun 30, 2022 | -45,691.67% |
| Mar 31, 2022 | 264.36% |
| Dec 31, 2021 | -102.56% |
| Sep 30, 2021 | -89.52% |
| Jun 30, 2021 | 51.75% |